OSP was delighted to speak to Galina Nesterova, executive medical director at the Rare Disease & Pediatrics Center of Excellence, and Susan McCune, vice president of pediatrics and clinical pharmacology both within medical science and strategy at...
With so many advanced therapies on the horizon, the next few years are poised to be one of significant progress for patients with over 2000 cell and gene therapies in active clinical trials globally.
Thermo Fisher’s clinical research subsidiary, PPD, invests $59 million in sample management and testing capacity for vaccines and cell and gene therapy products with its expansion of laboratory operations in Kentucky.
The company opens a bioanalytical lab in the US, which offers an additional 59,000-square-feet of space to the overall facility, making it “one of the largest laboratories of its kind.”
The company, through its subsidiary, PPD, announced that it had created a network that would provide learning materials to those investigators and research sites looking to use decentralized clinical trials (DCTs) for drug development.
OSP’s list of the year’s most-read stories shows readers are interested in M&A activities, new drug candidates, COVID-19 developments, and other hot news.
An academic researcher and and company expert discuss on how evolving cryogenic electron microscopy has led to high resolutions and accelerated results.
A representative from Thermo Fisher Scientific addresses how bringing research and resources directly to participants can address problems with studies.
The chairman, president and CEO of Thermo Fisher says the acquisition stands to benefit clinical trial and drug development clients in a long list of ways.
Thermo Fisher Scientific will partner with AstraZeneca and the University of Nebraska Medical Center to advance biomarker discovery and characterization.
The purchase is aimed at expanding the company’s specialty diagnostics offerings in sample preparation technology, assay capabilities, bioinformatics and more.
Thermo Fisher Scientific doubles the capacity of its gene therapy and viral vector processing facility in Alachua, Florida, to provide scalability to customers.
Regardless of the quality of the raw materials used in bioproduction processes, variability is a very common threat that can be addressed, says Thermo Fisher executive.
Clinical trials often rely on outsourced testing which poses potential logistical and cost challenges, though researchers recently demonstrated the viability of bringing these tests in-house to speed turnaround time – and more quickly match patients to...
Thermo Fisher Scientific bolsters its gene therapy capabilities by acquiring Brammer Bio for $1.7bn, as the market becomes an ‘increasing focus’ for customers.
Patheon is “better positioned” to serve clients following the Thermo Fisher Scientific Inc. acquisition, says CDMO president, whose initial focus will be integration.
Bioprocessing suppliers have recently expressed optimism in the sector despite a slowdown in growth, and one expert believes this will drive investment in new tech and markets.
The laboratories will participate in oncology-focused clinical trials as the program’s preferred partners and will be among the first to access Thermo Fisher’s pipeline of novel platforms and assays.
Thermo Fisher says Patheon will become the most competitive biologics CDMO in the market through direct access to its bioprocessing technologies and capabalities.
Thermo Fisher Scientific says it is buying Finesse Solutions, its long-term supplier of measurement and control solutions for bioprocessing applications.
South Korea is a key opportunity for biopharma services firms says Thermo Fisher, reporting its third quarter which saw it up capabilities in the region.
Chinese authorities have given Thermo Fisher Scientific the green light to buy Life Technologies on the condition it discounts certain products sold in the coutry.
Over the last decade single-use technologies have moved into manufacturing scales and are increasingly being deployed worldwide, according to Thermo Fisher Scientific.
Outsourcing-Pharma.com presents its weekly round-up of the latest movers and shakers in the world of pharmaceuticals, including news from Chiltern, Thermo Fisher and Penn Pharma.
Thermo Fisher Scientific has set up a unit for molecular biology techs at its site in Lithuania, citing pharmaceutical R&D labs in Eastern Europe as a target.
in-PharmaTechnologist presents its weekly round-up of the latest new appointments within the pharmaceutical industry, including news from Thermo Fisher, Stemline and ImmunoCellular.
Japanese researchers look set to have another option for biomarker analysis, after Thermo Fisher Scientific unveils plans for Tokyo research laboratory unit.
Thermo Fisher Scientific hopes that the web functionality offered by the latest generation of its Darwin LIMS system will help it become the natural selection for drug makers seeking an all-in-one QA solution.
Thermo Fisher has launched a new spectrometer that
incorporates FT-IR technology for improved clarity and detail,
aimed at pharmaceutical process scientists and other chemical
disciplines.
Thermo Fisher Scientific aims to make automation in the drug
discovery lab a whole lot easier through the development of an
articulated robot specifically designed for pharmaceutical
applications.
Thermo Fisher Scientific has opened a new RNAi Discovery and
Therapeutics Services Laboratory to help pharmaceutical companies
in their quest for new drugs.
